November 2, 2012
ImmuVen Receives $297,000 Phase I Award from NIH
- ImmuVen was recently awarded a Phase I SBIR totaling more than $297,000 from the National Institute of Allergy and Infectious Disease (NIAID). This grant will further the development of ImmuVen’s proprietary soluble, high-affinity T cell receptor technology for use in detection of toxins from Staphylococcal aureus in clinical samples as well as in the food supply. This new award comes on the heals of a Phase II SBIR from NIAID to continue ImmuVen’s work on soluble, high-affinity T cell receptors as a therapeutic for neutralizing S. aureus toxins involved in various diseases. “The awarding of NIH grants not only enables our continued scientific progress, but also serves as a validation of ImmuVen’s T cell receptor technology platform,” says Cheryl Quinn, CEO of ImmuVen, Inc.
April 1, 2012
ImmuVen Receives $1.67 Million Phase II SBIR Award From NIH
- ImmuVen was awarded a Phase II SBIR totaling $1.67 million from the National Institute for Allergy and Infectious Disease for continuing development of therapeutics to neutralize Staphylococcal aureus toxins. For more information, click here.
ImmuVen engineers T cell receptors for use as soluble biotherapeutics or in adoptive T cell therapies. Using a proprietary T cell receptor platform, multiple programs for novel cancer therapies are in development. ImmuVen has generated scaffold T cell receptor libraries for discovery and improvement of T cell receptors. Lead receptors against specific cancer targets are the focus of both internal development and co-development with partners. The company is located in Champaign, Illinois at the University of Illinois Research Park.